





# **COVER PAGE AND DECLARATION**

	Master of Business Administration (M.B.A.)
Specialisation:	MBA in Leadership
Affiliated Center:	CEO Business School
Module Code & Module Title:	MGT570: Financial Management
Student's Full Name:	AMIRA ABDULMALEK HEJJO
Student ID:	EIU2020319
Word count:	4000
Date of Submission:	09/ 05/ 2022

I confirm that this assignment is my own work, is not copied from any other person's work (published/unpublished), and has not been previously submitted for assessment elsewhere.

E-SIGNATURE:	Amira Abdulmalek	непо
DATE:	09/ 05/2022	

**EIU Paris City Campus** 

Address: 59 Rue Lamarck, 75018 Paris, France | Tel: +33 144 857 317 | Mobile/WhatsApp: +33607591197 | Email:paris@eiu.ac EIU Corporate Strategy & Operations Headquarter

Address: 12th Fl. Amarin Tower, 496-502 Ploenchit Rd., Bangkok 10330, Thailand | Tel: +66(2)256923 & +66(2)2569908 | Mobile/WhatsApp: +33607591197 | Email: info@eiu.ac

## Table of Content:

Information about ALmarai company	2
Statement of cashflow	5
Statement of financial position	6
Statement of profit or loss	7
Interim financial statement	8
Balance sheet	9
Consolidated income statement	14
Consolidated Statement of Financial Position	15
Consolidated Statement of Cash Flows	15
Company performance appraisal	18
Suggestions and recommendations to improve Almarai Company	22
Incom Statement Future Assumptions	24
Decide whether or not the ALMaraia company should pay return earnings or not	28
Recommendations for the company	29
References	3

#### Financial evaluation and analysis.

#### Almarai Dairy Company has been selected

#### Information about the company's activity and history was selected for its financial analysis.

#### **Almarai Company**

(the 'Company') is a Saudi joint stock company, which has been converted from a limited liability company. to a joint stock company

On Rajab 2, 1426 (corresponding to August 8, 2005 AD). The company started its commercial operations on Dhul Hijjah 19, 1411

(corresponding to July 1, 1991G) and operates under Commercial Registration No. 1010084223. Before the consolidation of its activities in 1991G, it was.

The main activities of the company for the years from 1977G until 1991G are carried out using the brand name "Almarai".

The address of the company's head office is Exit 7, Northern Ring Road, Al Izdihar District, P.O. 8524, Riyadh11492, Kingdom of Saudi Arabia

The Company and its subsidiaries (together the 'Group') are a major integrated group of consumer food and beverages in the region of

The Middle East, with the largest market share in Saudi Arabia. It also operates in the Gulf Cooperation Council countries.

Others, in addition to Egypt and Jordan.

Dairy, fruit juices, and food processing are produced using the brand names 'Almarai' and "Juicy Life"

And "Betty" and "Taiba". Raw milk is also produced and processed, while dairy foods and fruit juices are processed in

Kingdom of Saudi Arabia, United Arab Emirates, Egypt and Jordan.

Milk and fruit juices and food processing are produced in Egypt and Jordan through the International Company for Dairy and Juice.

Ltd., a joint venture with PepsiCo, in which the company retains a controlling interest. The group manages operations

Operating the International Dairy and Juice Company Ltd. through the following main subsidiaries:

Jordan - Taiba Investment and Advanced Food Industries Company

Egypt - International Company for Agricultural Industrial Projects (Bayti) (Egyptian Joint Stock Company)

Bakery products are manufactured and traded by Western Bakeries Company Limited, the Modern Company for Food Industry

Ltd. through a partnership with Chipita, in which the company maintains a controlling interest, using the two brand names.

Lusine and Seven Days, respectively.

Baby food is produced by Almarai Baby Food Company Limited and is sold by International Food Company Children under the brand name "Nuralac" and "Evolac".

In the countries in which the Group operates, the final consumer products are distributed from the manufacturing facilities to the centers

Local distribution by the long-distance fleet. All distribution centers in the GCC are managed By subsidiaries in the UAE, Oman and Bahrain and an agency agreement concluded in Kuwait as follows: United Arab Emirates - Almarai Emirates Company Limited

Sultanate of Oman - Arabian Planets Trading and Marketing Company Ltd. Kingdom of Bahrain - Almarai Bahrain Company W.L.L.

State of Kuwait - Al-Kharafi Brothers Dairy Products Co. Ltd.

In other countries, if the system permits, export sales are made through other subsidiaries.

The group owns and operates feed farms in Argentina and the USA. They are collectively referred to.

"Fondomonte", through the following main subsidiaries:

USA - Vondomonte Holdings North America Limited

ARGENTINA - FONDOMOTE SOUTH AMERICA S.A.

The Group's business outside the Gulf Cooperation Council is operated and managed by the International Dairy and Juice Company Limited



The data received from the company, according to the official reports, showed the following criteria. All the rules and procedures specified for the financial analysis process were followed to obtain the accurate results of the analysis for the past four years. The cash flow statements, the balance sheet and the statement of financial position were based on determining the rules of financial analysis for profitability, efficiency, and long-term and short-term solvency

The following has been done

profitability analysis 🖜

Efficiency Analysis 🖘

Short- and long-term solvency analysis 🖘

Company's future prospects

**Recommendations and suggestions** 

ALMARAI COMPANY A SAUDI JOINT STOCK COMPANY CONDENSED
CONSOLIDATED STATEMENT OF CASH FLOWS

CASH FLOWS FROM OPERATING ACTIVITIES         SAR 7000         SAR 7000           Prolit for the period         367,394         336,948           Adjustments for non-cash items.         401,165         386,904           Depreciation of Pight-of-Use Assets         25,981         25,979           Amortisation of linght-of-Use Assets         12,711         12,151           Depreciation of Bilotogical Assets         177,090         88,712           Loss Arising from Changes in Fair Value less Cost to Sell of Crops         11,209         11,491           Provision for Employee Retirement Benefits         30,355         33,625           Share Based Payment Expense         4,883         2,930           Finance Cost, net         124,875         126,419           Other Expenses, net         491         116,422           Share of Results of Associates and Joint Venture         5         1,598         -           Zakat         12,985         15,334           Income Tax         5,913         7,609           Changes in working capital.         1         1,064,022           Inventories         463,129         378,055           Biological Assets         346,071         339,441           Trade and Other Payables         (80,523)         42,223 </th <th></th> <th>Notes</th> <th>31 March 2020</th> <th>31 March 2019</th>		Notes	31 March 2020	31 March 2019
CASH FLOWS FROM OPERATING ACTIVITIES           Profit for the period         367,394         336,948           Adjustments for non-cash items.         25,981         25,679           Depreciation of Property, Plant and Equipment         401,165         386,904           Depreciation of Right-of-Use Assets         25,981         25,479           Amortisation of Intangible Assets         12,711         12,151           Depreciation of Biological Assets         77,990         88,712           Loss Arising from Changes in Fair Value less Cost to Sell of Crops         11,209         111,491           Provision for Employee Retirement Benefits         30,355         33,623           Share Based Payment Expense         4,883         2,930           Finance Cost, net         124,875         126,419           Other Expenses, net         491         16,422           Share of Results of Associates and Joint Venture         5         1,598         -           Zakat         12,985         15,334           Income Tax         5,913         7,609           Changes in working capital.         1,076,650         1,064,022           Changes in working capital.         463,129         378,055           Biological Assets         (34,007)         (339,441)		Notes	(Unaudited)	(Unaudited)
Profit for the period         367,394         336,948           Adjustments for non-cash items.         Depreciation of Property, Plant and Equipment         401,165         386,904           Depreciation of Right-of-Use Assets         25,981         25,479           Amortisation of Intangible Assets         12,711         12,151           Depreciation of Biological Assets         77,090         88,712           Loss Arising from Changes in Fair Value less Cost to Sell of Crops         11,209         114,991           Provision for Employee Retirement Benefits         30,355         33,623           Share Based Payment Expense         4,883         2,930           Finance Cost, net         124,875         126,6419           Other Expenses, net         491         16,422           Share of Results of Associates and Joint Venture         5         1,598         -           Zakat         12,985         15,334         1,006         1,006,022           Changes in working capital.         1076,650         1,006,022         1,006,002         1,006,002           Changes in working capital.         1,006,002         378,055         1,006,002         1,006,002           Changes in working capital.         1,006,002         3,006,002         1,006,002         1,006,002         1,0			SAR '000	SAR '000
Adjustments for non-cash items   Depreciation of Property, Plant and Equipment   401,165   386,904   Depreciation of Right-of-Use Assets   25,981   25,479   Amortisation of Intangible Assets   12,711   12,151   Depreciation of Biological Assets   77,090   88,712   Loss Arising from Changes in Fair Value less Cost to Sell of Crops   11,209   11,491   Provision for Employee Retirement Benefits   30,355   33,623   Share Based Payment Expense   4,883   2,930   Eniance Cost, net   124,875   126,419   16,422   Share of Results of Associates and Joint Venture   5   1,598   - 1,2985   15,334   Income Tax   12,985   15,334   Income Tax   1,000				
Depreciation of Property, Plant and Equipment         401,165         386,904           Depreciation of Right-of-Use Assets         25,981         25,479           Amortisation of Intangible Assets         11,2711         12,151           Depreciation of Biological Assets         77,090         88,712           Loss Arising from Changes in Fair Value less Cost to Sell of Crops         11,209         11,491           Provision for Employee Retirement Benefits         30,355         33,623           Share Based Payment Expense         4,883         2,930           Finance Cost, net         124,875         126,419           Other Expenses, net         491         16,422           Share of Results of Associates and Joint Venture         5         1,598         -           Zakat         12,985         15,334           Income Tax         5,913         7,609           Changes in working capital:         1,076,650         1,064,022           Changes in working capital:         1,076,650         1,064,022           Changes in working capital:         1,076,650         1,064,022           Trade and Other Payables         (644,704)         (258,234)           Trade and Other Payables         (60,000)         (60,000)           Cash Flow Used in Working Capi	·		367,394	336,948
Depreciation of Right-of-Use Assets   25,981   25,479	•			
Amortisation of Intangible Assets         12,711         12,151           Depreciation of Biological Assets         77,090         88,712           Loss Arising from Changes in Fair Value less Cost to Sell of Crops         11,209         11,499           Provision for Employee Retirement Benefits         30,355         33,623           Share Based Payment Expense         4,883         2,930           Finance Cost, net         124,875         126,419           Other Expenses, net         491         16,422           Share of Results of Associates and Joint Venture         5         1,598         -           Zakat         12,985         15,334           Income Tax         5,913         7,609           Changes in working capital.         1,076,650         1,064,022           Inventories         463,129         378,055           Biological Assets         (346,071)         (339,441)           Trade Receivables, Prepayments and Other Receivables         (644,704)         (258,234)           Trade and Other Payables         (80,523)         (42,293)           Cash Flow Used in Working Capital         (90,000)         (29,710)         (18,547)           Employee Retirement Benefits Paid         (29,710)         (18,547)           Zakat and Incom				
Depreciation of Biological Assets         77,090         88,712           Loss Arising from Changes in Fair Value less Cost to Sell of Crops         11,209         11,491           Provision for Employee Retirement Benefits         30,355         33,623           Share Based Payment Expense         4,883         2,930           Finance Cost, net         124,875         126,419           Other Expenses, net         491         16,422           Share of Results of Associates and Joint Venture         5         1,598         -           Zakat         12,985         15,334         1           Income Tax         5,913         7,609           Changes in working capital.         1         1,076,650         1,064,022           Changes in working capital.         463,129         378,055         3         1,056         1         1,064,022           Changes in working capital.         463,129         378,055         3         1,064,022         3         1,076,550         1,064,022           Biological Assets         (346,071)         (339,441)         1         1         2,052,334         4         2,233         4         2,233         4         2,233         4         2,233         4         2,233         4         2,233 <td></td> <td></td> <td></td> <td></td>				
Description   Changes in Fair Value   less Cost to Sell of Crops   11,209   11,491	•			
Provision for Employee Retirement Benefits         30,355         33,623           Share Based Payment Expense         4,883         2,930           Finance Cost, net         124,875         126,419           Other Expenses, net         491         16,422           Share of Results of Associates and Joint Venture         5         1,598         -           Zakat         12,985         15,334           Income Tax         5,913         7,609           Inventories         463,129         378,055           Biological Assets         (346,071)         (339,441)           Trade Receivables, Prepayments and Other Receivables         (644,704)         (258,234)           Trade and Other Payables         (80,523)         (42,293)           Cash Flow Used in Working Capital         (608,169)         (261,913)           Employee Retirement Benefits Paid         (29,710)         (18,547)           Zakat and Income Tax Paid         (54,679)         (1,473)           Net Cash Generated from Operating Activities         384,092         782,089           CASH FLOWS FROM INVESTING ACTIVITIES           Dividend from Equity Investment         58,000         -           Additions to Property, Plant and Equipment         45,608         12,282 <td></td> <td></td> <td></td> <td></td>				
Share Based Payment Expense         4,883         2,930           Finance Cost, net         124,875         126,419           Other Expenses, net         491         16,422           Share of Results of Associates and Joint Venture         5         1,598         -           Zakat         12,985         15,334           Income Tax         1,076,650         1,064,022           Changes in working capital.         463,129         378,055           Inventories         463,129         378,055           Biological Assets         (346,071)         (339,441)           Trade Receivables, Prepayments and Other Receivables         (644,704)         (258,234)           Trade and Other Payables         (80,523)         (42,293)           Cash Flow Used in Working Capital         (608,169)         (261,913)           Employee Retirement Benefits Paid         (29,710)         (18,547)           Zakat and Income Tax Paid         (54,679)         (1,473)           Net Cash Generated from Operating Activities         384,092         782,089           CASH FLOWS FROM INVESTING ACTIVITIES           Dividend from Equity Investment         -         300           Proceeds from Redemption of Time Deposit         585,000         -				
Finance Cost, net         124,875         126,419           Other Expenses, net         491         16,422           Share of Results of Associates and Joint Venture         5         1,598         -           Zakat         12,985         15,334           Income Tax         5,913         7,609           Changes in working capital.         1,076,650         1,064,022           Inventories         463,129         378,055           Biological Assets         (346,071)         (339,441)           Trade Receivables, Prepayments and Other Receivables         (644,704)         (258,234)           Trade and Other Payables         (80,523)         (42,293)           Cash Flow Used in Working Capital         (608,169)         (261,913)           Employee Retirement Benefits Paid         (29,710)         (18,547)           Zakat and Income Tax Paid         (54,679)         (1,473)           Net Cash Generated from Operating Activities         384,092         782,089           CASH FLOWS FROM INVESTING ACTIVITIES         5         300           Dividend from Equity Investment         -         300           Proceeds from Redemption of Time Deposit         585,000         -           Additions to Property, Plant and Equipment         45,608	. ,			
Other Expenses, net         491         16,422           Share of Results of Associates and Joint Venture         5         1,598         -           Zakat         12,985         15,334           Income Tax         5,913         7,609           Changes in working capital.         1,076,650         1,064,022           Inventories         463,129         378,055           Biological Assets         (346,071)         (339,441)           Trade Receivables, Prepayments and Other Receivables         (644,704)         (258,234)           Trade and Other Payables         (80,523)         (42,293)           Cash Flow Used in Working Capital         (608,169)         (261,913)           Employee Retirement Benefits Paid         (29,710)         (18,547)           Zakat and Income Tax Paid         (54,679)         (1,473)           Net Cash Generated from Operating Activities         384,092         782,089           CASH FLOWS FROM INVESTING ACTIVITIES         Dividend from Equity Investment         -         300           Proceeds from Redemption of Time Deposit         585,000         -           Additions to Property, Plant and Equipment         (241,368)         (466,484)           Proceeds from the Disposal of Property, Plant and Equipment         45,608         12,282	· · ·			,
Share of Results of Associates and Joint Venture         5         1,598         -           Zakat         12,985         15,334           Income Tax         5,913         7,609           1,076,650         1,064,022           Changes in working capital-         463,129         378,055           Inventories         463,129         378,055           Biological Assets         (346,071)         (339,441)           Trade Receivables, Prepayments and Other Receivables         (644,704)         (258,234)           Trade and Other Payables         (80,523)         (42,293)           Cash Flow Used in Working Capital         (608,169)         (261,913)           Employee Retirement Benefits Paid         (29,710)         (18,547)           Zakat and Income Tax Paid         (54,679)         (1,473)           Net Cash Generated from Operating Activities         384,092         782,089           CASH FLOWS FROM INVESTING ACTIVITIES         585,000         -           Dividend from Equity Investment         -         300           Proceeds from Redemption of Time Deposit         585,000         -           Additions to Property, Plant and Equipment         45,608         12,282           Additions to Intangible Assets         (31,274)         (30,247)				
Zakat         12,985         15,334           Income Tax         5,913         7,609           1,076,650         1,064,022           Changes in working capital.         463,129         378,055           Biological Assets         (346,071)         (339,441)           Trade Receivables, Prepayments and Other Receivables         (644,704)         (258,234)           Trade and Other Payables         (80,523)         (42,293)           Cash Flow Used in Working Capital         (608,169)         (261,913)           Employee Retirement Benefits Paid         (29,710)         (18,547)           Zakat and Income Tax Paid         (54,679)         (1,473)           Net Cash Generated from Operating Activities         384,092         782,089           CASH FLOWS FROM INVESTING ACTIVITIES         Dividend from Equity Investment         -         300           Proceeds from Redemption of Time Deposit         585,000         -           Additions to Property, Plant and Equipment         45,608         12,282           Additions to Intangible Assets         (31,274)         (30,247)           Additions to Biological Assets         (27,780)         (28,294)           Appreciation of Biological Assets         (141,698)         (153,167)           Proceeds from the Disposal		_		16,422
Income Tax         5,913         7,609           1,076,650         1,076,650         1,064,022           Changes in working capital.         Inventories         463,129         378,055           Biological Assets         (346,071)         (339,441)           Trade Receivables, Prepayments and Other Receivables         (644,704)         (258,234)           Trade and Other Payables         (80,523)         (42,293)           Cash Flow Used in Working Capital         (608,169)         (261,913)           Employee Retirement Benefits Paid         (29,710)         (18,547)           Zakat and Income Tax Paid         (54,679)         (1,473)           Net Cash Generated from Operating Activities         384,092         782,089           CASH FLOWS FROM INVESTING ACTIVITIES         500         -           Dividend from Equity Investment         -         300           Proceeds from Redemption of Time Deposit         585,000         -           Additions to Property, Plant and Equipment         (241,368)         (466,484)           Proceeds from the Disposal of Property, Plant and Equipment         45,608         12,282           Additions to Intangible Assets         (31,274)         (30,247)           Additions to Biological Assets         (111,698)         (153,167		5		
Changes in working capital.       1,076,650       1,064,022         Inventories       463,129       378,055         Biological Assets       (346,071)       (339,441)         Trade Receivables, Prepayments and Other Receivables       (644,704)       (258,234)         Trade and Other Payables       (80,523)       (42,293)         Cash Flow Used in Working Capital       (608,169)       (261,913)         Employee Retirement Benefits Paid       (29,710)       (18,547)         Zakat and Income Tax Paid       (54,679)       (1,473)         Net Cash Generated from Operating Activities       384,092       782,089         CASH FLOWS FROM INVESTING ACTIVITIES         Dividend from Equity Investment       -       300         Proceeds from Redemption of Time Deposit       585,000       -         Additions to Property, Plant and Equipment       (241,368)       (466,484)         Proceeds from the Disposal of Property, Plant and Equipment       45,608       12,282         Additions to Intangible Assets       (31,274)       (30,247)         Additions to Biological Assets       (27,780)       (28,294)         Appreciation of Biological Assets       51,618       59,776				
Changes in working capital.         463,129         378,055           Biological Assets         (346,071)         (339,441)           Trade Receivables, Prepayments and Other Receivables         (644,704)         (258,234)           Trade and Other Payables         (80,523)         (42,293)           Cash Flow Used in Working Capital         (608,169)         (261,913)           Employee Retirement Benefits Paid         (29,710)         (18,547)           Zakat and Income Tax Paid         (54,679)         (1,473)           Net Cash Generated from Operating Activities         384,092         782,089           CASH FLOWS FROM INVESTING ACTIVITIES         585,000         -           Dividend from Equity Investment         -         300           Proceeds from Redemption of Time Deposit         585,000         -           Additions to Property, Plant and Equipment         (241,368)         (466,484)           Proceeds from the Disposal of Property, Plant and Equipment         45,608         12,282           Additions to Intangible Assets         (31,274)         (30,247)           Additions to Biological Assets         (27,780)         (28,294)           Appreciation of Biological Assets         (141,698)         (153,167)           Proceeds from the Disposal of Biological Assets         51,61	Income Tax			
Inventories         463,129         378,055           Biological Assets         (346,071)         (339,441)           Trade Receivables, Prepayments and Other Receivables         (644,704)         (258,234)           Trade and Other Payables         (80,523)         (42,293)           Cash Flow Used in Working Capital         (608,169)         (261,913)           Employee Retirement Benefits Paid         (29,710)         (18,547)           Zakat and Income Tax Paid         (54,679)         (1,473)           Net Cash Generated from Operating Activities         384,092         782,089           CASH FLOWS FROM INVESTING ACTIVITIES         585,000         -           Dividend from Equity Investment         -         300           Proceeds from Redemption of Time Deposit         585,000         -           Additions to Property, Plant and Equipment         (241,368)         (466,484)           Proceeds from the Disposal of Property, Plant and Equipment         45,608         12,282           Additions to Intangible Assets         (31,274)         (30,247)           Additions to Biological Assets         (27,780)         (28,294)           Appreciation of Biological Assets         (141,698)         (153,167)           Proceeds from the Disposal of Biological Assets         51,618         <	Observed in wedting and to		1,076,650	1,064,022
Biological Assets         (346,071)         (339,441)           Trade Receivables, Prepayments and Other Receivables         (644,704)         (258,234)           Trade and Other Payables         (80,523)         (42,293)           Cash Flow Used in Working Capital         (608,169)         (261,913)           Employee Retirement Benefits Paid         (29,710)         (18,547)           Zakat and Income Tax Paid         (54,679)         (1,473)           Net Cash Generated from Operating Activities         384,092         782,089           CASH FLOWS FROM INVESTING ACTIVITIES         585,000         -           Dividend from Equity Investment         -         300           Proceeds from Redemption of Time Deposit         585,000         -           Additions to Property, Plant and Equipment         (241,368)         (466,484)           Proceeds from the Disposal of Property, Plant and Equipment         45,608         12,282           Additions to Intangible Assets         (31,274)         (30,247)           Additions to Biological Assets         (27,780)         (28,294)           Appreciation of Biological Assets         (141,698)         (153,167)           Proceeds from the Disposal of Biological Assets         51,618         59,776			462 120	279.055
Trade Receivables, Prepayments and Other Receivables         (644,704)         (258,234)           Trade and Other Payables         (80,523)         (42,293)           Cash Flow Used in Working Capital         (608,169)         (261,913)           Employee Retirement Benefits Paid         (29,710)         (18,547)           Zakat and Income Tax Paid         (54,679)         (1,473)           Net Cash Generated from Operating Activities         384,092         782,089           CASH FLOWS FROM INVESTING ACTIVITIES         -         300           Proceeds from Redemption of Time Deposit         585,000         -           Additions to Property, Plant and Equipment         (241,368)         (466,484)           Proceeds from the Disposal of Property, Plant and Equipment         45,608         12,282           Additions to Intangible Assets         (31,274)         (30,247)           Additions to Biological Assets         (27,780)         (28,294)           Appreciation of Biological Assets         (141,698)         (153,167)           Proceeds from the Disposal of Biological Assets         51,618         59,776				•
Trade and Other Payables         (80,523)         (42,293)           Cash Flow Used in Working Capital         (608,169)         (261,913)           Employee Retirement Benefits Paid         (29,710)         (18,547)           Zakat and Income Tax Paid         (54,679)         (1,473)           Net Cash Generated from Operating Activities         384,092         782,089           CASH FLOWS FROM INVESTING ACTIVITIES         -         300           Proceeds from Redemption of Time Deposit         585,000         -           Additions to Property, Plant and Equipment         (241,368)         (466,484)           Proceeds from the Disposal of Property, Plant and Equipment         45,608         12,282           Additions to Intangible Assets         (31,274)         (30,247)           Additions to Biological Assets         (27,780)         (28,294)           Appreciation of Biological Assets         (141,698)         (153,167)           Proceeds from the Disposal of Biological Assets         51,618         59,776	•			
Cash Flow Used in Working Capital         (608,169)         (261,913)           Employee Retirement Benefits Paid         (29,710)         (18,547)           Zakat and Income Tax Paid         (54,679)         (1,473)           Net Cash Generated from Operating Activities         384,092         782,089           CASH FLOWS FROM INVESTING ACTIVITIES         -         300           Dividend from Equity Investment         -         300           Proceeds from Redemption of Time Deposit         585,000         -           Additions to Property, Plant and Equipment         (241,368)         (466,484)           Proceeds from the Disposal of Property, Plant and Equipment         45,608         12,282           Additions to Intangible Assets         (31,274)         (30,247)           Additions to Biological Assets         (27,780)         (28,294)           Appreciation of Biological Assets         (141,698)         (153,167)           Proceeds from the Disposal of Biological Assets         51,618         59,776				
Employee Retirement Benefits Paid         (29,710)         (18,547)           Zakat and Income Tax Paid         (54,679)         (1,473)           Net Cash Generated from Operating Activities         384,092         782,089           CASH FLOWS FROM INVESTING ACTIVITIES         Substitution of Time Deposit         -         300           Proceeds from Redemption of Time Deposit         585,000         -           Additions to Property, Plant and Equipment         (241,368)         (466,484)           Proceeds from the Disposal of Property, Plant and Equipment         45,608         12,282           Additions to Intangible Assets         (31,274)         (30,247)           Additions to Biological Assets         (27,780)         (28,294)           Appreciation of Biological Assets         (141,698)         (153,167)           Proceeds from the Disposal of Biological Assets         51,618         59,776	·			
Zakat and Income Tax Paid         (54,679)         (1,473)           Net Cash Generated from Operating Activities         384,092         782,089           CASH FLOWS FROM INVESTING ACTIVITIES         Use a contract of the property of the propert				
Net Cash Generated from Operating Activities         384,092         782,089           CASH FLOWS FROM INVESTING ACTIVITIES         585,000         -           Dividend from Equity Investment         -         300           Proceeds from Redemption of Time Deposit         585,000         -           Additions to Property, Plant and Equipment         (241,368)         (466,484)           Proceeds from the Disposal of Property, Plant and Equipment         45,608         12,282           Additions to Intangible Assets         (31,274)         (30,247)           Additions to Biological Assets         (27,780)         (28,294)           Appreciation of Biological Assets         (141,698)         (153,167)           Proceeds from the Disposal of Biological Assets         51,618         59,776	. ,			
CASH FLOWS FROM INVESTING ACTIVITIES           Dividend from Equity Investment         -         300           Proceeds from Redemption of Time Deposit         585,000         -           Additions to Property, Plant and Equipment         (241,368)         (466,484)           Proceeds from the Disposal of Property, Plant and Equipment         45,608         12,282           Additions to Intangible Assets         (31,274)         (30,247)           Additions to Biological Assets         (27,780)         (28,294)           Appreciation of Biological Assets         (141,698)         (153,167)           Proceeds from the Disposal of Biological Assets         51,618         59,776				
Dividend from Equity Investment         -         300           Proceeds from Redemption of Time Deposit         585,000         -           Additions to Property, Plant and Equipment         (241,368)         (466,484)           Proceeds from the Disposal of Property, Plant and Equipment         45,608         12,282           Additions to Intangible Assets         (31,274)         (30,247)           Additions to Biological Assets         (27,780)         (28,294)           Appreciation of Biological Assets         (141,698)         (153,167)           Proceeds from the Disposal of Biological Assets         51,618         59,776	Net Cash Generated from Operating Activities		384,092	/82,089
Proceeds from Redemption of Time Deposit         585,000         -           Additions to Property, Plant and Equipment         (241,368)         (466,484)           Proceeds from the Disposal of Property, Plant and Equipment         45,608         12,282           Additions to Intangible Assets         (31,274)         (30,247)           Additions to Biological Assets         (27,780)         (28,294)           Appreciation of Biological Assets         (141,698)         (153,167)           Proceeds from the Disposal of Biological Assets         51,618         59,776	CASH FLOWS FROM INVESTING ACTIVITIES			
Additions to Property, Plant and Equipment       (241,368)       (466,484)         Proceeds from the Disposal of Property, Plant and Equipment       45,608       12,282         Additions to Intangible Assets       (31,274)       (30,247)         Additions to Biological Assets       (27,780)       (28,294)         Appreciation of Biological Assets       (141,698)       (153,167)         Proceeds from the Disposal of Biological Assets       51,618       59,776	Dividend from Equity Investment			300
Proceeds from the Disposal of Property, Plant and Equipment       45,608       12,282         Additions to Intangible Assets       (31,274)       (30,247)         Additions to Biological Assets       (27,780)       (28,294)         Appreciation of Biological Assets       (141,698)       (153,167)         Proceeds from the Disposal of Biological Assets       51,618       59,776	Proceeds from Redemption of Time Deposit		585,000	
Additions to Intangible Assets       (31,274)       (30,247)         Additions to Biological Assets       (27,780)       (28,294)         Appreciation of Biological Assets       (141,698)       (153,167)         Proceeds from the Disposal of Biological Assets       51,618       59,776	Additions to Property, Plant and Equipment		(241,368)	(466,484)
Additions to Biological Assets         (27,780)         (28,294)           Appreciation of Biological Assets         (141,698)         (153,167)           Proceeds from the Disposal of Biological Assets         51,618         59,776	Proceeds from the Disposal of Property, Plant and Equipment		45,608	12,282
Appreciation of Biological Assets         (141,698)         (153,167)           Proceeds from the Disposal of Biological Assets         51,618         59,776	Additions to Intangible Assets		(31,274)	(30,247)
Proceeds from the Disposal of Biological Assets 51,618 59,776	Additions to Biological Assets		(27,780)	(28,294)
	Appreciation of Biological Assets		(141,698)	(153,167)
Net Cash Generated From / (Used in) Investing Activities 240,106 (605,834)	Proceeds from the Disposal of Biological Assets		51,618	59,776
	Net Cash Generated From / (Used in) Investing Activities		240,106	(605,834)

## **STATEMENT OF FINANCIAL POSITION**

Non-Current Assets   Property, Plant and Equipment   22,882,735   23,038,263   Intangible Assets and Goodwill   1,146,611   1,128,533   Intangible Assets and Goodwill   1,146,611   1,128,533   Investments in Associate and Joint Venture   5   86,693   88,029   Equity Investment   5   112,427   145,684   Investments in Associate and Joint Venture   5   86,693   88,029   Investment   5   112,427   145,684   Investment   133   725   Inventories   141,125   Inventories   140,001,47   Inventories   140,00		Notes	31 March 2020 (Unaudited)	31 December 2019 (Audited)
Non-Current Assets         Froperty, Plant and Equipment         22,882,735         23,038,263           Intangible Assets and Goodwill         1,146,611         1,128,533           Biological Assets         1,386,439         1,381,268           Investments in Associate and Joint Venture         5         86,693         88,029           Equity Investment         5         112,427         145,684           Derivative Financial Instruments         133         725           Deferred Tax Assets         41,125         40,836           Inventories         4,050,147         4,198,005           Biological Assets         119,032         96,462           Trade Receivables, Prepayments and Other Receivables         2,516,041         1,868,995           Derivative Financial Instruments         9,599         13,751           Time Deposit         -         9,003           Cash and Bank Balances         376,029         557,553           TOTAL ASSETS         37,070,488         7,324,704           Total ASSETS         4,000,000         10,000,000           Stare Capital         6         10,000,000           Stare Capital         6         10,000,000           Stare Capital         6         10,000,000		•	SAR '000	SAR '000
Property, Plant and Equipment         22,882,735         23,038,263           Intangible Assets and Goodwill         1,146,611         1,28,533           Biological Assets         1,386,439         1,381,268           Investments in Associate and Joint Venture         5         86,693         88,029           Equity Investment         5         112,427         145,684           Derivative Financial Instruments         133         725           Deferred Tax Assets         41,125         40,836           Current Assets           Inventories         4,050,147         4,198,005           Biological Assets         119,032         96,462           Trade Receivables, Prepayments and Other Receivables         25,16,041         1,868,995           Derivative Financial Instruments         9,599         13,751           Time Deposit         5         376,029         557,553           Cash and Bank Balances         376,029         557,553           TOTAL ASSETS         33,148,042         7,070,848         7,324,704           TOTAL ASSETS         32,237,701         33,148,042           Equity AND LIABILITIES         6         10,000,000         10,000,000           Statutory Reserve         2230,479         2,2	ASSETS			
Intangible Assets and Goodwill         1,146,611         1,128,533           Biological Assets         1,386,439         1,381,268           Investments in Associate and Joint Venture         5         86,693         88,029           Equity Investment         5         112,427         145,684           Derivative Financial Instruments         133         725           Deferred Tax Assets         41,125         40,836           Current Assets           Inventories         4,050,147         4,198,005           Biological Assets         119,032         96,462           Trade Receivables, Prepayments and Other Receivables         2,516,041         1,868,995           Derivative Financial Instruments         9,599         13,751           Time Deposit         -         590,038           Cash and Bank Balances         376,029         557,553           TOTAL ASSETS         37,002,402         557,553           EQUITY AND LIABILITIES         3,148,042         7,070,848         7,324,704           Treasury Shares         (1,015,120)         (770,740)         14,653,349           Other Reserves         (540,614)         (450,587)         14,653,349           Fequity Attributable to Equity Holders of the Company <t< td=""><td>Non-Current Assets</td><td></td><td></td><td></td></t<>	Non-Current Assets			
Biological Assets         1,386,439         1,381,286           Investments in Associate and Joint Venture         5         86,693         88,029           Equity Investment         5         112,427         145,684           Derivative Financial Instruments         133         7.25           Deferred Tax Assets         41,125         40,836           Current Assets         41,125         40,836           Inventories         4,050,147         4,198,005           Biological Assets         119,032         96,462           Trade Receivables, Prepayments and Other Receivables         2,516,041         1,868,895           Derivative Financial Instruments         9,599         13,751           Time Deposit         2         7,070,848         7,324,704           Total Assets         376,029         557,553           Total Assets         376,029         557,553           Total Assets         32,727,011         33,148,042           EQUITY AND LIABILITIES         1         0         0           Star Capital         6         10,000,000         10,000,000           Statutory Reserve         2,230,479         2,230,479         2,230,479           Treasury Shares         (1,015,120)         (770	Property, Plant and Equipment		22,882,735	23,038,263
Investments in Associate and Joint Venture         5         86,693         88,029           Equity Investment         5         112,427         145,684           Derivative Financial Instruments         133         725           Deferred Tax Assets         41,125         40,836           Current Assets           Inventories         4,050,147         4,198,005           Biological Assets         119,032         96,462           Trade Receivables, Prepayments and Other Receivables         2,516,041         1,868,895           Derivative Financial Instruments         9,599         13,751           Time Deposit         -         590,038           Cash and Bank Balances         376,029         557,553           TOTAL ASSETS         30,700,048         7,324,704           TOTAL ASSETS         32,727,011         33,148,042           EQUITY AND LIABILITIES         5         10,000,000         10,000,000           Statutory Reserve         2,230,479         2,230,479         2,230,479           Treasury Shares         (1,015,120)         (770,740)           Other Reserves         (540,614)         (450,587)           Retained Earnings         4,049,515         3,644,197           Equity Attr	Intangible Assets and Goodwill		1,146,611	1,128,533
Equity Investment         5         112,427         145,684           Derivative Financial Instruments         133         725           Deferred Tax Assets         41,125         40,836           Current Assets           Inventories         4,050,147         4,198,005           Biological Assets         119,032         96,462           Trade Receivables, Prepayments and Other Receivables         2,516,041         1,868,895           Derivative Financial Instruments         9,599         13,751           Time Deposit         -         590,038           Cash and Bank Balances         37,070,848         7,324,704           TOTAL ASSETS         376,029         557,533           EQUITY AND LIABILITIES         4         10,000,000           Statutory Reserve         2,230,479         2,230,479           Treasury Shares         (1,015,120)         (770,740)           Other Reserves         (540,614)         (450,587)           Retained Earnings         4,049,515         3,644,197           Equity Attributable to Equity Holders of the Company         14,724,260         14,653,349           Non-Controlling Interests         597,228         605,771	Biological Assets		1,386,439	1,381,268
Derivative Financial Instruments         133         725           Deferred Tax Assets         41,125         40,836           Current Assets         25,656,163         25,823,338           Current Assets         8         4,050,147         4,198,005           Biological Assets         119,032         96,462           Trade Receivables, Prepayments and Other Receivables         2,516,041         1,868,895           Derivative Financial Instruments         9,599         13,751           Time Deposit         -         590,038           Cash and Bank Balances         376,029         557,533           TOTAL ASSETS         37,002,48         7,324,704           TOTAL ASSETS         32,272,011         33,148,042           EQUITY AND LIABILITIES         6         10,000,000         10,000,000           Statutory Reserve         2,230,479         2,230,479           Treasury Shares         (1,015,120)         (770,740           Other Reserves         (540,614)         (450,587)           Retained Earnings         4,049,515         3,644,197           Equity Attributable to Equity Holders of the Company         14,724,260         14,653,349           Non-Controlling Interests         597,228         605,771 <td>Investments in Associate and Joint Venture</td> <td>5</td> <td>86,693</td> <td>88,029</td>	Investments in Associate and Joint Venture	5	86,693	88,029
Deferred Tax Assets         41,125         40,836           Current Assets         25,656,163         25,823,338           Inventories         4,050,147         4,198,005           Biological Assets         119,032         96,462           Trade Receivables, Prepayments and Other Receivables         2,516,041         1,868,895           Derivative Financial Instruments         9,599         13,751           Time Deposit         2         590,038           Cash and Bank Balances         376,029         557,553           TOTAL ASSETS         37,702,848         7,324,704           TOTAL ASSETS         32,727,011         33,148,042           EQUITY AND LIABILITIES         5         32,227,011         33,148,042           EQUITY AND LIABILITIES         6         10,000,000         10,000,000           Statutory Reserve         2,230,479         2,230,479           Treasury Shares         (1,015,120)         (770,740           Other Reserves         (540,614)         (450,587           Retained Earnings         4,049,515         3,644,197           Equity Attributable to Equity Holders of the Company         14,724,260         14,653,349           Non-Controlling Interests         597,228         605,771 <td>Equity Investment</td> <td>5</td> <td>112,427</td> <td>145,684</td>	Equity Investment	5	112,427	145,684
Current Assets         25,656,163         25,823,338           Inventories         4,050,147         4,198,005           Biological Assets         119,032         96,462           Trade Receivables, Prepayments and Other Receivables         2,516,041         1,868,895           Derivative Financial Instruments         9,599         13,751           Time Deposit         -         590,038           Cash and Bank Balances         376,029         557,553           TOTAL ASSETS         32,727,011         33,148,042           EQUITY AND LIABILITIES         40,000,000         10,000,000           Statutory Reserve         2,230,479         2,230,479           Treasury Shares         (1,015,120)         (770,740)           Other Reserves         (540,614)         (450,587)           Retained Earnings         4,049,515         3,644,197           Equity Attributable to Equity Holders of the Company         14,724,260         14,653,349           Non-Controlling Interests         597,228         605,771	Derivative Financial Instruments		133	725
Current Assets         4,050,147         4,198,005           Biological Assets         119,032         96,462           Trade Receivables, Prepayments and Other Receivables         2,516,041         1,868,895           Derivative Financial Instruments         9,599         13,751           Time Deposit         -         590,038           Cash and Bank Balances         376,029         557,553           TOTAL ASSETS         32,770,0848         7,324,704           TOTAL ASSETS         32,727,011         33,148,042           EQUITY AND LIABILITIES         59,000         10,000,000           Statutory Reserve         2,230,479         2,230,479           Treasury Shares         (1,015,120)         (770,740)           Other Reserves         (540,614)         (450,587)           Retained Earnings         4,049,515         3,644,197           Equity Attributable to Equity Holders of the Company         14,724,260         14,653,349           Non-Controlling Interests         597,228         605,771	Deferred Tax Assets		41,125	40,836
Inventories         4,050,147         4,198,005           Biological Assets         119,032         96,462           Trade Receivables, Prepayments and Other Receivables         2,516,041         1,868,895           Derivative Financial Instruments         9,599         13,751           Time Deposit         -         590,038           Cash and Bank Balances         376,029         557,553           TOTAL ASSETS         32,727,011         33,148,042           EQUITY AND LIABILITIES         5         10,000,000           Share Capital         6         10,000,000         10,000,000           Statutory Reserve         2,230,479         2,230,479           Treasury Shares         (1,015,120)         (770,740)           Other Reserves         (540,614)         (450,587)           Retained Earnings         4,049,515         3,644,197           Equity Attributable to Equity Holders of the Company         14,724,260         14,653,349           Non-Controlling Interests         597,228         605,771		_	25,656,163	25,823,338
Biological Assets         119,032         96,462           Trade Receivables, Prepayments and Other Receivables         2,516,041         1,868,895           Derivative Financial Instruments         9,599         13,751           Time Deposit         -         590,038           Cash and Bank Balances         376,029         557,553           TOTAL ASSETS         32,727,011         33,148,042           EQUITY AND LIABILITIES         5         10,000,000         10,000,000           Share Capital         6         10,000,000         10,000,000           Statutory Reserve         2,230,479         2,230,479           Treasury Shares         (1,015,120)         (770,740)           Other Reserves         (540,614)         (450,587)           Retained Earnings         4,049,515         3,644,197           Equity Attributable to Equity Holders of the Company         14,724,260         14,653,349           Non-Controlling Interests         597,228         605,771	Current Assets	_		
Trade Receivables, Prepayments and Other Receivables         2,516,041         1,868,895           Derivative Financial Instruments         9,599         13,751           Time Deposit         -         590,038           Cash and Bank Balances         376,029         557,553           TOTAL ASSETS         32,727,011         33,148,042           EQUITY AND LIABILITIES         5         5           Share Capital         6         10,000,000         10,000,000           Statutory Reserve         2,230,479         2,230,479         770,740           Treasury Shares         (1,015,120)         (770,740)         770,740           Other Reserves         (540,614)         (450,587)           Retained Earnings         4,049,515         3,644,197           Equity Attributable to Equity Holders of the Company         14,724,260         14,653,349           Non-Controlling Interests         597,228         605,771	Inventories		4,050,147	4,198,005
Derivative Financial Instruments         9,599         13,751           Time Deposit         -         590,038           Cash and Bank Balances         376,029         557,553           TOTAL ASSETS         7,070,848         7,324,704           EQUITY AND LIABILITIES         32,727,011         33,148,042           Share Capital         6         10,000,000         10,000,000           Statutory Reserve         2,230,479         2,230,479         2,230,479           Treasury Shares         (1,015,120)         (770,740)           Other Reserves         (540,614)         (450,587)           Retained Earnings         4,049,515         3,644,197           Equity Attributable to Equity Holders of the Company         14,724,260         14,653,349           Non-Controlling Interests         597,228         605,771	Biological Assets		119,032	96,462
Time Deposit         590,038           Cash and Bank Balances         376,029         557,553           TOTAL ASSETS         7,070,848         7,324,704           EQUITY AND LIABILITIES         32,727,011         33,148,042           Share Capital         6         10,000,000         10,000,000           Statutory Reserve         2,230,479         2,230,479           Treasury Shares         (1,015,120)         (770,740)           Other Reserves         (540,614)         (450,587)           Retained Earnings         4,049,515         3,644,197           Equity Attributable to Equity Holders of the Company         14,724,260         14,653,349           Non-Controlling Interests         597,228         605,771	Trade Receivables, Prepayments and Other Receivables		2,516,041	1,868,895
Cash and Bank Balances         376,029         557,553           TOTAL ASSETS         7,070,848         7,324,704           EQUITY AND LIABILITIES         33,148,042           Share Capital         6         10,000,000         10,000,000           Statutory Reserve         2,230,479         2,230,479           Treasury Shares         (1,015,120)         (770,740)           Other Reserves         (540,614)         (450,587)           Retained Earnings         4,049,515         3,644,197           Equity Attributable to Equity Holders of the Company         14,724,260         14,653,349           Non-Controlling Interests         597,228         605,771	Derivative Financial Instruments		9,599	13,751
TOTAL ASSETS         7,070,848         7,324,704           EQUITY AND LIABILITIES           Share Capital         6         10,000,000         10,000,000           Statutory Reserve         2,230,479         2,230,479           Treasury Shares         (1,015,120)         (770,740)           Other Reserves         (540,614)         (450,587)           Retained Earnings         4,049,515         3,644,197           Equity Attributable to Equity Holders of the Company         14,724,260         14,653,349           Non-Controlling Interests         597,228         605,771	Time Deposit			590,038
TOTAL ASSETS         32,727,011         33,148,042           EQUITY AND LIABILITIES         5 10,000,000         10,000,000           Statutory Reserve         2,230,479         2,230,479           Treasury Shares         (1,015,120)         (770,740)           Other Reserves         (540,614)         (450,587)           Retained Earnings         4,049,515         3,644,197           Equity Attributable to Equity Holders of the Company         14,724,260         14,653,349           Non-Controlling Interests         597,228         605,771	Cash and Bank Balances	_	376,029	557,553
EQUITY AND LIABILITIES           Share Capital         6         10,000,000         10,000,000           Statutory Reserve         2,230,479         2,230,479           Treasury Shares         (1,015,120)         (770,740)           Other Reserves         (540,614)         (450,587)           Retained Earnings         4,049,515         3,644,197           Equity Attributable to Equity Holders of the Company         14,724,260         14,653,349           Non-Controlling Interests         597,228         605,771		_	7,070,848	7,324,704
Share Capital         6         10,000,000         10,000,000           Statutory Reserve         2,230,479         2,230,479           Treasury Shares         (1,015,120)         (770,740)           Other Reserves         (540,614)         (450,587)           Retained Earnings         4,049,515         3,644,197           Equity Attributable to Equity Holders of the Company         14,724,260         14,653,349           Non-Controlling Interests         597,228         605,771	TOTAL ASSETS	-	32,727,011	33,148,042
Statutory Reserve         2,230,479         2,230,479           Treasury Shares         (1,015,120)         (770,740)           Other Reserves         (540,614)         (450,587)           Retained Earnings         4,049,515         3,644,197           Equity Attributable to Equity Holders of the Company         14,724,260         14,653,349           Non-Controlling Interests         597,228         605,771	EQUITY AND LIABILITIES			
Statutory Reserve         2,230,479         2,230,479           Treasury Shares         (1,015,120)         (770,740)           Other Reserves         (540,614)         (450,587)           Retained Earnings         4,049,515         3,644,197           Equity Attributable to Equity Holders of the Company         14,724,260         14,653,349           Non-Controlling Interests         597,228         605,771	Share Capital	6	10,000,000	10,000,000
Treasury Shares         (1,015,120)         (770,740)           Other Reserves         (540,614)         (450,587)           Retained Earnings         4,049,515         3,644,197           Equity Attributable to Equity Holders of the Company         14,724,260         14,653,349           Non-Controlling Interests         597,228         605,771	•			2,230,479
Other Reserves         (540,614)         (450,587)           Retained Earnings         4,049,515         3,644,197           Equity Attributable to Equity Holders of the Company         14,724,260         14,653,349           Non-Controlling Interests         597,228         605,771	,		(1,015,120)	(770,740)
Equity Attributable to Equity Holders of the Company14,724,26014,653,349Non-Controlling Interests597,228605,771	•		(540,614)	(450,587)
Equity Attributable to Equity Holders of the Company14,724,26014,653,349Non-Controlling Interests597,228605,771	Retained Earnings		4,049,515	3,644,197
Non-Controlling Interests 597,228 605,771	•	-	14,724,260	14,653,349
TOTAL EQUITY 15,321,488 15,259,120				
	TOTAL EQUITY	•	15,321,488	15,259,120

## **STATEMENT OF PROFIT OR LOSS**

		31 March 2020	31 March 2019
	Notes	(Unaudited)	(Unaudited)
		SAR '000	SAR '000
Revenue	9	3,592,440	3,308,892
Cost of Sales		(2,339,247)	(2,144,986)
Gross Profit		1,253,193	1,163,906
Selling and Distribution Expenses		(611,569)	(564,538)
General and Administration Expenses		(99,828)	(94,754)
Other Expenses, net		(491)	(16,422)
Impairment Loss on Financial Assets		(28,540)	(1,882)
Operating Profit		512,765	486,310
Finance Cost, net		(124,875)	(126,419)
Share of Results of Associate and Joint Venture	5	(1,598)	
Profit before Zakat and Income Tax	•	386,292	359,891
Zakat		(12,985)	(15,334)
Income Tax		(5,913)	(7,609)
Profit for the period		367,394	336,948
Profit / (Loss) for the period attributable to:			
Shareholders of the Company		383,005	336,028
Non-Controlling Interests		(15,611)	920
•	,	367,394	336,948
Earnings per share (SAR), based on Profit for the period attributable to Shareholders of the Company			
- Basic	8	0.39	0.34
- Diluted	8	0.38	0.34

		31 March	31 December
	Notes	2020	2019
		(Unaudited)	(Audited)
		SAR '000	SAR '000
LOANS AND BORROWINGS			
Islamic Banking Facilities (Murabaha)		5,452,249	5,119,508
Saudi Industrial Development Fund		2,677,227	2,665,478
Banking Facilities of Non-GCC Subsidiaries		398,956	363,296
Supranational		277,046	276,099
Agricultural Development Fund		162,253	159,173
		8,967,731	8,583,554
Sukuk	7.1	1,612,283	2,408,180
International Sukuk		1,871,230	1,891,986
		12,451,244	12,883,720
Short-Term Loans		84,720	51,419
Current Portion of Long-Term Loans		1,073,686	1,934,974
Loans and Borrowings - Current Liabilities		1,158,406	1,986,393
Loans and Borrowings - Non-Current Liabilities		11,292,838	10,897,327
		12,451,244	12,883,720

Description	Dec. 2018		Dec. 2	Dec. 2019		Dec. 2020		Dec. 2021		
·	Amount	%	Amount	%	Amount	%	Amount	%		
			<u>Assets</u>							
				Fig EGP'0				Fig EGP'0		
Current Assets				00				00		
Cash & Cash Equv.										
	1,182,90	16.62								
Cash & Banks	2	%	557,553	7.57%	503,510	6.87%	580,913	8.13%		
<u>Receivables</u>										
biological Assests	98,439	1.38%	96,462	1.31%	90,195	1.23%	117,980	1.65%		
	1,929,94	27.12		25.37		26.43		27.86		
Accounts Receivables	9	%	1,868,895	%	1,936,341	%	1,991,205	%		
Derivative Financial	00.000	0.000/	40.754	0.400/	54047	0.740/	44.507	0.400/		
Instrument	20,336	0.29%	13,751	0.19%	54,047	0.74%	11,597	0.16%		
lny contony	3,874,19	54.43 %	4 400 005	57.00	4 70E 264	64.24	4,353,596	60.91		
Inventory	3		4,198,005		4,705,364		4,353,596			
Prepaid Expenses	44.400	0.00%	10.000	0.00%	05.547	0.00%	45.000	0.00%		
Withhold Taxes	11,488	0.16%	40,836	0.55%	35,517	0.48%	45,339	0.63%		
Time deposit		0.00%	590,038	8.01%		0.00%		0.00%		
Equity Investment		0.00%		0.00%		0.00%	46,894	0.66%		
Total Current Accets	7,117,30	100%	7,365,540	100%	7,324,974	100%	7,147,524	100%		
Total Current Assets	/	100%	7,365,540	100%	1,324,914	100%	7,147,524	100%		
Allowers of the Doubtful										
Allowance for Doubtful Rec.		0%		0%		0%		0%		
Total Net Current	7,117,30	0 70		0 76		0 76		0 76		
Assets	7,117,30	100%	7,365,540	100%	7,324,974	100%	7,147,524	100%		
<u>Fixed-Assets</u>										
	1,366,56									
Land	6	5.42%	1,381,268	5.36%	1,392,079	5.56%	1,469,084	5.97%		
Desilation of	1,038,37	4.400/	4 400 500	4.000/	4 047 040	4.070/	4 400 405	4.500/		
Building	1	4.12% 89.70	1,128,533 21,951,39		1,217,642		1,129,105			
Equipments	22,606,5 42	%	8	%	21,112,90 4	%	20,873,44	%		
Long Term Payment	72	0.00%	625,490	2.43%	606,939	2.43%	579,677	2.36%		
Right of Use Assets				1.79%	470,269	1.88%	-			
		0.00%	461,375		470,269		464,704	1.89%		
Computers & Program	204	0.00%		0.00%		0.00%		0.00%		
Furnitures & Stationary	204	0.00%		0.00%		0.00%		0.00%		
prepayment	67,059	0.27%		0.00%		0.00%		0.00%		
Investment in associates and joint venture 204		0.00%	88,029	0.34%	89,623	0.36%	88,749	0.36%		
	102 624						00,749			
Equity envestment Derivative Finanacial	102,624	0.41%	145,684	0.57%	129,734	0.52%		0.00%		
instrument	19,747	0.08%	725	0.00%	142	0.00%	2,011	0.01%		
inotratificit.	25,201,1	89.97	25,782,50		25,019,33		24,606,77	89.07		
Total Fixed Assets	13	%	25,762,30	%	25,019,55	%	8	%		

Acc. Depreciation	0	0.00%		0.00%		0.00%		0.00%
7.00. Doprodiation		0.0070		0.0070		0.0070		0.0070
**	25,201,1		25,782,50		25,019,33		24,606,77	
Total Net Fixed Assets	13		2		2		8	
Other Leves Town								
Other Long Term Assets								
<u> </u>		#DIV/		#DIV/		#DIV/		#DIV/
Accounts Receivables		0!	0	0!	0	0!	0	0!
		#DIV/		#DIV/		#DIV/		#DIV/
Deffered Taxes		0! #DIV/	0	0! #DIV/	0	0! #DIV/	0	0! #DIV/
		#DIV/ 0!		#DIV/ 0!		#DIV/		#DIV/
		#DIV/		#DIV/		#DIV/		#DIV/
		0!		0!		0!		0!
		#DIV/		#DIV/		#DIV/		#DIV/
Total Fixed Assets	0	0!	0	0!	0	0!	0	0!
	7 117 20	22.02		22.22		22.65		22.51
Total Net Current Assets	7,117,30	22.02 %	7,365,540	22.22 %	7,324,974	22.65 %	7,147,524	22.51 %
Total Not Call One 7 locots	25,201,1	#DIV/	25,782,50	#DIV/	25,019,33		24,606,77	
Total Net Fixed Assets	13	0!	2	0!	2	%	8	%
Total Other Long Term								
Assets	0	0.00% <b>#DIV/</b>	0 <b>33,148,04</b>	0.00% <b>#DIV/</b>	0 <b>32,344,30</b>	0.00% <b>100.0</b>	0 <b>31,754,30</b>	0.00% <b>100.0</b>
Total Balance Sheet	32,318,4 20	#DIV/	2	#DIV/	6	0%	2	0%
				-		0.0		
		E	Balance Sho	eet				
Description	201		Balance Sho		202	0	202	1
Description	Amount	8 %	2019 Amount	9 %	Amount	0 %	202 Amount	1 %
Description	Amount	8 %	201	9 % Iders Ed	Amount			%
•	Amount	8 %	2019 Amount	9 % Iders Ed	Amount			% Fig
Current laibilities/	Amount	8 %	2019 Amount	9 % Iders Ed	Amount			%
Current laibilities/ Provision Derivative financial	Amount Li	8 % abilities	Amount & Shareho	% Iders Ed Fig EGP'0 00	Amount	%	Amount	Fig EGP'0 00
Current laibilities/ Provision Derivative financial Instruments	Amount <u>Li</u>	8 % abilities	Amount & Shareho	%	Amount quity 4,271	0.4%	<b>Amount</b> 46,594	Fig EGP'0 00
Current laibilities/ Provision Derivative financial Instruments Bank overdrafts	Amount <u>Li</u> 26,322 179,321	8 % abilities	Amount & Shareho	% Iders Ed Fig EGP'0 00	Amount	%	Amount	Fig EGP'0 00
Current laibilities/ Provision Derivative financial Instruments Bank overdrafts Short-Term Loans/	26,322 179,321 2,010,29	1.3% 56.7%	9,166 219,118	%  ders Ed   Fig   EGP'0   00   0.4%   55.5%	4,271 137,512	0.4% 34.5%	46,594 78,395	Fig EGP'0 00 1.7% 17.5%
Current laibilities/ Provision Derivative financial Instruments Bank overdrafts Short-Term Loans/ Borrowings	Amount <u>Li</u> 26,322 179,321	8 % abilities	Amount & Shareho	%  ders Ed   Fig   EGP'0   00   0.4%   55.5%	Amount quity 4,271	0.4% 34.5%	<b>Amount</b> 46,594	Fig EGP'0 00 1.7% 17.5%
Current laibilities/ Provision Derivative financial Instruments Bank overdrafts Short-Term Loans/	26,322 179,321 2,010,29	1.3% 56.7%	9,166 219,118	%  ders Ed   Fig   EGP'0   00   0.4%   55.5%	4,271 137,512	0.4% 34.5%	46,594 78,395	Fig EGP'0 00 1.7% 17.5%
Current laibilities/ Provision Derivative financial Instruments Bank overdrafts Short-Term Loans/ Borrowings Zakat and Text Incom Payable	26,322 179,321 2,010,29 4 316,064 2,874,06	1.3% 56.7% 69.9%	9,166 219,118 2,082,143 395,066	%	4,271 137,512 1,120,522 398,304	0.4% 34.5% 37.2% 8.5%	46,594 78,395 2,712,308 447,252	Fig EGP'0 00 1.7% 17.5% 81.2% 6.8%
Current laibilities/ Provision Derivative financial Instruments Bank overdrafts Short-Term Loans/ Borrowings Zakat and Text Incom	26,322 179,321 2,010,29 4 316,064 2,874,06 6	1.3% 56.7%	9,166 219,118 2,082,143	%	4,271 137,512 1,120,522	0.4% 34.5% 37.2% 8.5%	46,594 78,395 2,712,308	Fig EGP'0 00 1.7% 17.5% 81.2% 6.8%
Current laibilities/ Provision Derivative financial Instruments Bank overdrafts Short-Term Loans/ Borrowings Zakat and Text Incom Payable Trad and other Payables	26,322 179,321 2,010,29 4 316,064 2,874,06 6 5,406,06	1.3% 56.7% 5.8% 53.2%	9,166 219,118 2,082,143 395,066 3,019,160	9 %	4,271 137,512 1,120,522 398,304 3,014,834	0.4% 34.5% 37.2% 8.5% 64.5%	46,594 78,395 2,712,308 447,252 3,339,496	Fig EGP'0 00 1.7% 17.5% 81.2% 6.8% 50.4%
Current laibilities/ Provision Derivative financial Instruments Bank overdrafts Short-Term Loans/ Borrowings Zakat and Text Incom Payable	26,322 179,321 2,010,29 4 316,064 2,874,06 6	1.3% 56.7% 69.9%	9,166 219,118 2,082,143 395,066	9 %	4,271 137,512 1,120,522 398,304	0.4% 34.5% 37.2% 8.5% 64.5%	46,594 78,395 2,712,308 447,252	Fig EGP'0 00 1.7% 17.5% 81.2% 6.8% 50.4%
Current laibilities/ Provision Derivative financial Instruments Bank overdrafts Short-Term Loans/ Borrowings Zakat and Text Incom Payable Trad and other Payables  Total Provision	26,322 179,321 2,010,29 4 316,064 2,874,06 6 5,406,06	1.3% 56.7% 5.8% 53.2%	9,166 219,118 2,082,143 395,066 3,019,160	9 %	4,271 137,512 1,120,522 398,304 3,014,834	0.4% 34.5% 37.2% 8.5% 64.5%	46,594 78,395 2,712,308 447,252 3,339,496	Fig EGP'0 00 1.7% 17.5% 81.2% 6.8% 50.4%
Current laibilities/ Provision Derivative financial Instruments Bank overdrafts Short-Term Loans/ Borrowings Zakat and Text Incom Payable Trad and other Payables	26,322 179,321 2,010,29 4 316,064 2,874,06 6 5,406,06	1.3% 56.7% 5.8% 53.2%	9,166 219,118 2,082,143 395,066 3,019,160	9 %	4,271 137,512 1,120,522 398,304 3,014,834	0.4% 34.5% 37.2% 8.5% 64.5%	46,594 78,395 2,712,308 447,252 3,339,496	Fig EGP'0 00 1.7% 17.5% 81.2% 6.8% 50.4%

Total Balance Sheet	32,318,4 20	100.0 0%	33,148,04	100.0 0%	32,344,30	100.0 0%	31,754,30	100.0 0%
Equity	90	%	0	%	9	%	3	%
Liabilities Total Shareholders	0 14,515,9	0.00% 44.92	0 15,259,12	0.00% 46.03	0 16,233,67	0.00% 50.19	16,618,41	0.00% 52.33
Total Current Liabilities  Total Long Term	30	%	2	%	7	70	9	%
Total Current Liabilities	17,802,4	55.08	17,888,92		16,110,62	49.81 %	15,135,88	
Equity	90	%	0	%	9	%	3	%
Total Shareholders	14,515,9	100.0	15,259,12		16,233,67		16,618,41	100.0
Return Earning		0.0%		0.0%		0.0%		0.0%
Profit for the Year		0.0%		0.0%		0.0%		0.0%
ShareHolder Account	000,104	0.0%	000,771	0.0%	0.10,771	0.0%	100,010	0.0%
13,926796 Non Controlling Interests	96 589,194	95.9% 4.1%	9 605,771	96.0% 4.0%	8 546,771	96.6% 3.4%	498,919	97.0% 3.0%
EquityAttributabletoEquit yHolders of comp	13,926,7		14,653,34		15,686,90		16,119,49	
Paid up Capital		0.0%		0.0%		0.0%		0.0%
Shareholders Equity								
Total Liabilities	30	%	2	%	7	%	9	%
	17,802,4	100.0	17,888,92		16,110,62		15,135,88	100.0
Long Term Debt	U	0.076	U	0.076	U	0.076		0.076
Long Term Debt	0	0.0%	0	0.0%	0	0.0%		0.0%
Long-Term Liabilities								
Total Current Liabilities	30	%	2	%	7	%	9	%
	17,802,4	100.0	17,888,92		16,110,62		15,135,88	100.0
Total Payables	63	69.6%	9	68.0%	4	71.0%	8,511,844	56.2%
•	12,396,3		12,164,26		11,435,18			
Other Payables		0.0%		0.0%		0.0%		0.0%
Banks Payable		0.0%		0.0%		0.0%		0.0%
Tax Payable		0.0%	333,039	0.0%	330,300	0.0%	300,434	0.0%
Defferd Tax Laibilities Lease Laibilities	37,967	0.3%	103,328 335,659	0.8% 2.8%	102,139 330,980	0.9% 2.9%	117,302 360,434	1.4% 4.2%
Instrument	7,101	0.1%	1,556	0.0%	3,757	0.0%	10,041	0.1%
Employee retirment Benefit Derivative Financial	699,325	5.6%	826,399	6.8%	909,353	8.0%	951,827	11.2%

Income Statement									
Description	Dec-15		Dec-16		Dec-	17	Dec-18		
	Amount	%	Amount	%	Amount	%	Amount	%	

	13,722,7	100.0	14,351,27	100.0	15,356,94	100.0	15,849,72	100.0
Net Sales	97	0%	7	0%	8	0%	0	0%
	(8,277,43	60.32	(8,984,60	62.60	(9,821,44	63.95	(10,790,4	68.08
COGS	5)	%	3)	%	0)	%	50)	%
	5,445,36	39.68		37.40		36.05		31.92
Gross Income	2	%	5,366,674	%	5,535,508	%	5,059,270	%
Operating Expenses			/		/		<i>'</i>	
G&A	(2,632,21 5)	2.74%	(2,376,32	16.56 %	(2,490,47	16.22 %	(2,518,85	15.89 %
Selling & Marketing Exp.	(376,475)	2.59%	(517,138)	3.60%	9) (522,695)	3.40%	(525,565)	3.32%
Delining & Marketing Exp.	24,684	2.5370	(317,130)	3.00 /6	(322,093)	3.40 /0	(323,303)	3.32 /0
	2,461,35	17.94		17.23		16.42		12.71
EBITDA	6	%	2,473,208	%	2,522,334	%	2,014,854	%
Depreciation &								
Amortization		0.00%		0.00%		0.00%		0.00%
Provisions				0.00%		0.00%		0.00%
	2,461,35	17.94		17.23		16.42		12.71
Operating Income "EBIT"	6	%	2,473,208	%	2,522,334	%	2,014,854	%
Other Income &								
<u>Expenses</u>				_		_		_
Other Revenues	29,524	0.22%	(550,739)	3.84%	(495,881)	3.23%	(346,063)	2.18%
			(,,		(, /	-	(,,	-
Interest Expenses	(407,747)	2.97%		0.00%	1,405	0.01%	(941)	0.01%
	(=·	-						
Other Expenses	(5,413)	0.04%		0.00%		0.00%		0.00%
				10.10		10.00		10.50
Pretax Income "EBT"	2,077,72	15.14 %	1,922,469	13.40 %	2,027,858	13.20 %	1,667,850	10.52 %
	-	N/A		N/A		N/A		N/A
Taxes	(70,498)	IN/A	(120,897)	IN/A	(92,302)	IN/A	(88,414)	IN/A
	2,007,22	14.63		12.55		12.60		
Net Income	2,007,22	%	1,801,572	%	1,935,556	%	1,579,436	9.97%
	_	,,	1,001,012	,,	1,000,000	7.0	1,010,100	0101 /0
	6,082,49		5,004,366		7,742,224		7,179,254	
Equity	0.91		.67		.00		.55	
		Cor	nparative R	atios				
Description	Dec-	15	42,70	)5	Dec-	17	43,43	35
Profitability Status								
Return on Sales "ROS"	14.63	%	12.55	%	12.60	%	9.97	%
Return on Assets "ROA"	6.21	%	5.43	%	17.75	%	21.00	%
Return on Equity "ROE"	33.00	%	36.00	%	25.00	%	22.00	%
Earning Per Share "EPS"	91.24	EGP	81.89	EGP	87.98	EGP	71.79	EGP
Liquidity Status								
Current Ratio	0.40	:1	0.41	:1	0.45	:1	0.47	:1
Quick Ratio	0.17	:1	0.14	:1	0.15	:1	0.17	:1
Cash Ratio	0.07	:1	0.03	:1	0.03	:1	0.04	:1

Working Capital	10,685,1 23	EGP	- 10,523,38 2	EGP	- 8,785,653	EGP	- 7,988,365	EGP
Efficiency Turnovers								
DIO	120	Days	89	Days	45	Days	48	Days
DSO	51	Days	47	Days	45	Days	45	Days
DPO	508	Days	441	Days	374	Days	240	Days
ccc	-338	Days	-305	Days	-283	Days	-147	Days
Leverage Status								
Total Debt / Equity	1.23	:1	1.17	:1	0.99	:1	0.91	:1
Total Debt / Total Assets	0.55	:1	0.54	:1	0.50	:1	0.48	:1

# **Consolidated Income Statement**

Consolidated	2017	2018	2019	2020	2021
Income Statement					
Revenue	13,935,532	13,557,837	14,351,277	15,356,948	15,849,720
Gross Profit	5,583,639	5,327,074	5,366,674	5,535,508	5,059,270
Operating Profit	2,583,350	2,521,235	2,473,208	2,522,334	2,014,854
Profit before Zakat	2,202,208	2,079,056	1,922,469	2,027,858	1,667,850
and income Tax					
Profit/(Loss) for the	2,182,286	2,011,975	1,811,753	1,984,361	1,563,543
year attributable to					
shareholders					
Profit for the year	2,159,963	2,008,558	1,801,572	1,935,556	1,579,436

## **Consolidated Statement of Financial Position**

Consolidated Statement of Financial Position	2017	2018	2019	2020	2021
Total assets	32,388,856	32,782,547	33,148,042	32,344,306	31,754,302
Non-current assets	25,610,948	25,693,475	25,823,338	25,054,849	24,652,117
Intangible Assets and Goodwill	1,046,607	1,038,371	1,128,533	1,217,642	1,129,105
Biological Asset	1,283,342	1,366,566	1,381,268	1,392,079	1,469,084
Investment	129,429	204	88,029	89,623	88,749
Current assets	6,777,908	7,089,072	7,324,704	7,289,457	7,102,185
Equity Attributable to Shareholders	12,731,054	13,876,583	14,653,349	15,686,908	16,119,494
Total equity	14,826,558	14,462,644	15,259,120	16,233,679	16,618,413
Non-current liabilities	11,743,683	12,806,066	12,164,269	11,435,184	8,511,844
Current liabilities	5,818,615	5,513,837	5,724,653	4,675,443	6,624,045

#### **Consolidated Statement of Cash Flows**

Consolidated	2017	2018	2019	2020	2021
Statement of					
Cash Flows					

Net cash generated from operating activities	4,614,147	3,668,772	4,732,081	4,203,052	4,915,005
Net cash used in investing activities	3,310,466	- 2,349,719	- 2,944,053	-787,627	- 1,814,247
Net cash generated from/(used in) financing activities	-240,992	- 1,960,927	2,460,038	3,250,039	- 3,023,761
Net increase / (decrease) in cash and cash equivalents	1,062,689	-641,874	-672,010	165,386	76,997
Cash and cash equivalents at end of period	1,636,112	1,003,581	338,435	503,510	580,913

Net income increased during the year 2020 by 5.9% compared to the previous year 2019, to reach 984.1 million Saudi riyals. Also, revenues increased by 7% to reach SAR 357.15 million. From On the other hand, economic pressures persisted in various markets The Gulf Cooperation Council (GCC) countries throughout the year, due to key to the COVID-19 pandemic, which continues to wreak havoc on . Supply chains and in the food and beverage sector as a whole world level. The business model adopted by the company has succeeded Almarai, which is

characterized by a high degree of integration, in mitigating The effects of fluctuation resulting from this pandemic are tangible, as it has been proven The distinguished procedures and controls implemented by the company are important in Ensuring the availability of sufficient quantities to meet consumer demand. Sales volume rose sharply during the early stages of the pandemic due to the closure measures quickly imposed by the Saudi government To ensure the safety and well-being of the population.

. Also witnessed the shopping movement in Retail outlets rose significantly as consumers rushed to stock up Amounts of supplies in anticipation of the continuation of the closure procedures for a long period, Because of the state of anxiety that prevailed in the market in general. It has proven Almarai company procedures of controlling the supply and distribution chain . Strategic products are effective and necessary to manage costs and ensure Availability of adequate supply of products. Almarai Company has modified its approach to ensure the safety of all its employees in light of the challenges witnessed by the market

. At the beginning During the pandemic, travel restrictions have resulted in the detention of 400,000 Our colleagues in Almarai Company outside the Kingdom were unable to return They were also unable to continue working before the company accelerated the implementation of Work from home protocols. And soon we took the steps. Necessary to facilitate the work of remote employees, with the exception of those working in Factories and farms, and we have implemented complete closure procedures for all sites Farms and production in a move aimed at reducing the exposure of these sites to the outside world as much as possible. These procedures have enabled teams field work continue their important work, keep fulfilling The year 2020 was an extraordinary year, which required an extraordinary response from us as well. Almarai's commitment to customers and consumers who choose our products synonymous with their commitment to achieving the highest levels of quality. With the market starting to shrink as a result of the pandemic spreading across the region

We must help achieve balance We had a feeling of duty Ensure that food shortages in the area are mitigated as much possible. Distinguished internal procedures and capabilities have been employed. The integrated distribution enjoyed by Almarai Company to meet the demand in all our major markets. We have all felt the impact of our commitment to providing our most important products. At first, the Almarai company experienced some disruption in operations and chain sales accompanied our transition to the 'new reality'. Although we are in A sector that is


considered one of the 'defensive' sectors, this does not mean that it will not be affected The company under the prevailing conditions, as we had to import large quantities of livestock feed and other raw materials, resulting in an increase Whoever understands it Significantly higher costs, although high Due to improved free cash flow of SAR 830.2 million Saudi. And with life returning to its course, although in a new way. According to the latest developments in the situation, it became clear to us that the measures we have taken It has been adopted as part of the company's framework in recent years With the aim of improving resilience, it has played an essential role in supporting our ability. To remain productive during these challenging times and to continue Fulfilling "Quality Worth Trusting". investment case study It is fully aware of the requirements to maintain customer loyalty while continuing to Made of the finest raw materials. Provide high-quality, manufactured products Market leadership Nearly the market in which it operates Almarai ranks first in all sectors • Almarai Company during the fiscal year 2019G center Occupy First according to the performance rating in the face of environmental risks and Social and Governance Risk (ESG) within companies in The Saudi Stock Exchange1. Stable growth in revenues and profits 2020, as revenues grew in all markets Almarai Company recorded a growth of 0.7% in revenues for except for Oman to reach 984.1 million Saudi riyals, compared to net income •Net income increased by 5.9% during the year 2020G to reach worth 812.1 million Saudi riyals last year Recording a lower expenditure volume of 969 million Saudi Riyals, tangibly improving capital expenditures, which led to This represents a decrease of more than 40% compared to the previous year. The volume of spending in it amounted to 650.1 million Saudi riyals. Outstanding Achievement in Creating Shareholder Value With a total value of SAR 1,000 million, a cash dividend of SAR 0.1 per share will be distributed. Paid to shareholders for the full year 2020 AD A 305% increase in the share price since the listing Rapid response to the COVID-19 pandemic, flexibility in facing external shocks The crisis thanks to the resilience of the supply chain The return of the company's product portfolio to pre-existing levels of casualties Crisis management teams mobilize to prepare for a possible "second wave" Essential • Procurement teams have successfully avoided interruptions in access to materials

Based on the balance sheet, the statement of cash flows and the income statement, the following results appear:

1Company performance appraisal

In terms of profitability, the value with Million:-


The profitability analysis shows the following.



Efficiency Efficiency analysis shows that the company's efficiency

increased in 2020 compared to previous years





# a-Short-tem Solvency

# the decrease in 2021 from 2020 according to the schedule;

Key indicators	2017	2018	2019	2020	2021
the decrease in 2021 from 2020					
according to the schedule;					
Return on Sales	15.5	14.8	12.6	12.6	10.0
EBITDA to Sales	28.1	29.7	28.0	26.1	22.0
EBIT to Sales	18.5	18.6	17.2	16.4	12.7

## d. Long-term Solvency

Key indicators	2017	2018	2019	2020	2021
Return on Shareholders Equity	17.9	15.1	12.6	12.8	9.9
Return on Total Equity	15.3	13.7	12.1	12.3	9.6
Return on Net Operating Assets	10.5	9.4	8.9	9.1	7.4

Revenue Growth Rate -2.8 -2.7 5.9 7.0 3.2

## e. Market-based Ratios

Key indicators	2017	2018	2019	2020	2021
We note a decrease in the					
existing percentages in the					
market in 2021 compared to all					
previous years					
Net Debt to Equity Ratio	73.3	88.0	78.0	66.0	55.0
Net Debt / EBITDA	2.8	3.2	3.0	2.7	2.6
Current Ratio	116.5	128.6	128.0	155.9	107.2
Stock information					
Dividend Proposed	750	850	850	1,000	1,000
Dividends Payout Ratio	34.0	42.0	47.0	50.0	60.0

Segmental Reporting	2017	2018	2019	2020	2021
Sales by segment					
Dairy & Juice	10,510.5	9,919.7	10,210.0	10,923.7	11,141.3
Bakery	1,807.1	1,641.4	1,749.3	1,712.0	1,788.9
Poultry	1,463.6	1,800.4	2,124.6	2,292.8	2,301.5
Other Activities	154.3	196.4	267.4	428.5	618.1
Sales by geography					
Saudi Arabia	9,300.0	9,179.8	9,737.3	10,285.9	10,222.8
Other GCC Countries	3,480.7	3,090.4	3,164.3	3,198.2	3,121.3
Other Countries	1,154.9	1,287.6	1,449.7	1,872.9	2,505.6
Sales analysis by country					
KSA	67.0	67.0	67.8	<mark>67.0</mark>	<mark>65.0</mark>
UAE	10.0	10.0	9.5	9.0	9.0
Oman	5.0	6.0	5.2	4.0	4.0
Kuwait	5.0	5.0	5.0	5.0	5.0
Egypt	5.0	6.0	5.9	6.0	8.0
Bahrain	2.0	2.0	2.3	2.0	2.0
Jordan	2.0	2.0	2.1	3.0	3.0
Other exports	2.0	2.0	2.2	3.0	4.0

We note from the table a decrease in the percentage of sales in Saudi Arabia and Egypt, and this is one of the biggest effects in the decrease in profit between the years 2021 and 2020.

We note the decrease in the company's net profit value between 2021 and 2020 by 356,120 Saudi riyals

Where the company's net profit for the year in 2020 was 1,935,556 riyals

The company's profit in 2021 was 1579436 riyals

Consequently, after the financial analysis of the revenue side, it is clarified that the main reason for this is the decrease in company sales than it was in 2020, which led to the weakness of the income side of the company, and this represents a great threat to the company because the company is supposed to grow its sales, but there is another reason to increase the sales side in 2020, namely increasing sales of foodstuffs in view of the Corona crisis, and my suggestion to the company is to increase marketing operations to expand the scope of the company's brand and increase supply, thus increase demand, as the company can reach in 2022 more than two million Saudi riyals, provided that the distribution scope of distribution be increased through marketing, reducing costs for the company and opening new markets. The company also gives a great possibility for the company to enter major investment opportunities.

#### **3- Incom Statement Future Assumptions:**

A-the company can make a new investment project, which is opening distribution points in new countries to increase the scope of sales through agents by opening offices and registering products in those countries. This investment project will be financed through through own capital.

Income Statement Future Assumptions :							
ltem	Yr-22	Yr-23	Yr-24	Yr-25	Yr-26	Yr-27	

Target Net Profit Before Taxes Rate	4%	6%	8%	10%	12%	14%	
Gross Profit Rate	31.0%	33.0%	35.2%	37.5%	40.3%	42.3%	
Interest Rate	2.0%	2.0%	2.0%	2.0%	2.0%	2.0%	
Sales & Marketing Rate	4.0%	4.0%	4.0%	4.0%	4.0%	4.0%	
G&A Expenses	3,000,000	3,450,000	3,967,500	4,562,625	5,247,009	6,054,072	
Deprication Expenses	750,000	750,000	750,000	750,000	750,000	750,000	
Item	Yr-22	Yr-23	Yr-24	Yr-25	Yr-26	Yr-27	
(+) Sales Revenues	17,857,14 3	20,000,000	22,252,358	24,709,884	26,892,41 7	30,511,53	
Sales Growth Rate	-51%	12%	11%	11%	9%	13%	
(-) COGS	12,321,42 9	13,400,000	14,419,528	15,443,677	16,054,77 3	17,605,15 5	
Gross Profit	5,535,714	6,600,000	7,832,830	9,266,206	10,837,64 4	12,906,37 9	
Gross Profit Rate	31%	33%	35%	38%	40%	42%	
SG&A							
Expenses							
(-) Sales & Marketing Expenses	714,286	800,000	890,094	988,395	1,075,697	1,220,461	
(-) G&A Expenses	3,000,000	3,450,000	3,967,500	4,562,625	5,247,009	6,054,072	
Total SG&A	3,714,286	4,250,000	4,857,594	5,551,020	6,322,706	7,274,533	
SG&A	21%	21%	22%	22%	24%	24%	
Expenses Rate							
•	1,821,429	2,350,000	2,975,236	3,715,186	4,514,938	5,631,845	

(-) Deprication Expenses	750,000	750,000	750,000	750,000	750,000	750,000
(+/-) EBIT	1,071,429	1,600,000	2,225,236	2,965,186	3,764,938	4,881,845
EBIT Rate	6%	8%	10%	12%	14%	16%
(-) Interest Expenses	357,143	400,000	445,047	494,198	537,848	610,231
(+/-) EBT	714,286	1,200,000	1,780,189	2,470,988	3,227,090	4,271,615
EBT Rate	4%	6%	8%	10%	12%	14%
(-) Income Taxes	160,714	270,000	400,542	555,972	726,095	961,113
(+/-) NI	553,571	930,000	1,379,646	1,915,016	2,500,995	3,310,501
NI Rate	3%	5%	6%	8%	9%	11%
<u>Multiplier</u> Model						
Valuation Multiplier at Yr-19:						
EBITDA@ 10X	18,214,28 6					
(-) Banking Facilities	0					
Enterprise Value	18,214,28 6					
Discounted Cash Flow Model						
Working Capital Calculations						
Item	Yr-22	Yr-23	Yr-24	Yr-25	Yr-26	Yr-27
DSO@ 60 days	2,976,190	3,333,333	3,708,726	4,118,314	4,482,070	5,085,256

DIO@ 45							
days	1,540,179	1,675,000	1,802,441	1,930,460	2,006,847	2,200,644	
DPO@ 60 days	2,053,571	2,233,333	2,403,255	2,573,946	2,675,795	2,934,192	
Other Debtors	892,857	1,000,000	1,112,618	1,235,494	1,344,621	1,525,577	
Other Creditors	357,143	400,000	445,047	494,198	537,848	610,231	
Working Capital	2,998,512	3,375,000	3,775,483	4,216,124	4,619,893	5,267,053	
Net Change in WC	0	-376,488	-400,483	-440,640	-403,769	-647,160	
DCF Valuation at Yr-19:	0	1	2	3	4	5	
Item	Yr-22	Yr-23	Yr-24	Yr-25	Yr-26	Yr-27	Terminal Value
(+) EBIT	1,071,429	1,600,000	2,225,236	2,965,186	3,764,938	4,881,845	
(-) Taxes	241,071	360,000	500,678	667,167	847,111	1,098,415	
Net Income	553,571	930,000	1,379,646	1,915,016	2,500,995	3,310,501	
(+) Deprication Exp	427,146	750,000	750,000	750,000	750,000	750,000	
(+) Change In WC	0	-376,488	-400,483	-440,640	-403,769	-647,160	
(-) CAPEX - Capital Expenditure	0	0	0	0	0	0	
Free Cash Flow	1,257,503	1,613,512	2,074,074	2,607,379	3,264,058	3,886,270	28,499,31
FCF Growth Rate		28%	29%	26%	25%	19%	
ltem	Yr-22	Yr-23	Yr-24	Yr-25	Yr-26	Yr-27	Terminal Value
Discount Rate @ 25.00%	1.000	1.250	1.563	1.953	2.441	3.052	3.052
PV	1,257,503	1,290,810	1,327,408	1,334,978	1,336,958	1,273,453	9,338,655
NPV	17,159,76 4						
(-) Banking Facilities	0						

Enterprise Value	17,159,76 4						
cash outflow	year1	year2	year3	year4	year5	year6	
(-2,500,0000)	1257503	1613512	2074074	2607379	3264058	3886270	
cach out flow							
present value of cash flow	1,006,002	1032647.6 8	1,061,925.8 9	1,067,982.4 4	1,069,566	1,018,762	
6,256,886							
NPV							
3756886							

4 The company does not have to pay those fees, as the company is currently suffering from a significant decrease in sales and must avoid any fees to address the decrease in profit from the previous year

#### **Company's future prospects**

Median / Actual (SAR Mn)		2021	2022e	2023e	2024e
Sales	111	<u>15,850</u>	<u>16,588</u>	<u>17,645</u>	<u>18,589</u>
Gross profit	1	<u>5,059</u>	<u>5,486</u>	<u>5,877</u>	<u>6,265</u>
EBITDA	Ш	<u>3,493</u>	<u>4,100</u>	<u>4,513</u>	<u>4,747</u>
Operating income	4	<u>2,015</u>	<u>2,313</u>	<u>2,586</u>	<u>2,747</u>
Income before tax	Ш	<u>1,668</u>	<u>1,941</u>	<u>2,150</u>	<u>2,362</u>
Income before minority interest	4	<u>1,579</u>	<u>1,828</u>	<u>2,042</u>	<u>2,230</u>
Netincome	111	<u>1,564</u>	<u>1,766</u>	<u>2,014</u>	<u>2,200</u>

#### **Recommendations for the company**

- 1- Increasing the number of markets inside the state of Egypt to increase sales
- 2- Increasing the volume of marketing within the Kingdom of Saudi Arabia to address the decline in sales due to it being a major local market for the company.
- 3- Increasing the volume of distribution and increasing the volume of supply of products within the local market
- 4- Making discounts and offers on the most requested products to encourage purchase.

- 5- Studying the behavior of the local consumer in order to meet his desires
- 6- Addressing high prices with high quality and after-sales service to the consumer
- 7- Increasing the spread and support of the community, which supports the company's brand in the future

#### **References:-**

- Analysis of Financial Statements:- U.S. Department of Agriculture-p3
- Analysis of Financial Statements -31- https://ncert.nic.in/ncerts/l/leac204.pdf
- -Financial Analysis & Forecasting- Prepared by Matt H. Evans, CPA, CMA, CFM p1
- -Financial Managment, by dr.Eslam Abdulhamid
- Financial Managmentm by Paramasivan & Subramanian
- -https://www.almarai.com/
- -https://www.fool.com
- -https://www.economist.com/
- -https://cs.thomsonreuters.com/ua/acct\_pr/fina/cs\_us\_en/pdfs/fina\_sample\_reports.pdf\_-p16
- -https://www.marketwatch.com/
- -https://ar.knoema.com/
- -Open Textbook library https://open.umn.edu/opentextbooks
- 2004- 2008 by Thomson Reuters/Tax & Accounting.